Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
therapeutics | D013812 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hyperphosphatemia | HP_0002905 | D054559 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | — | N18 | 1 | 8 | 15 | 4 | 5 | 33 |
Hyperphosphatemia | D054559 | HP_0002905 | — | 2 | 5 | 14 | 2 | 7 | 29 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 3 | 8 | 1 | 3 | 16 |
Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 3 | 1 | 1 | 5 |
Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | 1 | — | 1 | 2 | 4 |
Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Calcinosis | D002114 | — | — | — | — | — | 1 | — | 1 |
Smallpox | D012899 | — | B03 | — | — | — | 1 | — | 1 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 2 | — | 1 | 4 |
Dialysis | D003956 | — | — | — | — | 1 | — | 1 | 2 |
Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | 1 | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Peritoneal dialysis | D010530 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 2 | — | — | 1 | 3 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 1 | — | — | — | 2 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | 1 | 2 |
Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | 1 | — | — | — | 1 |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | 1 | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 3 | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 3 | 3 |
Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 2 | 2 |
Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 2 | 2 |
Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
Drug common name | Sevelamer |
INN | sevelamer |
Description | Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
|
Classification | Small molecule |
Drug class | polymers |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C=CCN.ClCC1CO1 |
PDB | — |
CAS-ID | 1392212-84-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1201798 |
ChEBI ID | — |
PubChem CID | 3085017 |
DrugBank | DB00658 |
UNII ID | 941N5DUU5C (ChemIDplus, GSRS) |